An Updated Analysis of Pembrolizumab (MK-3475) for Melanoma
Jedd D. Wolchok, MD, PhD, discusses an updated analysis presented at the 2014 ASCO Annual Meeting that looked at pembrolizumab (MK-3475) for patients with melanoma.
Clinical Pearls
Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an updated analysis presented at the 2014 ASCO Annual Meeting that looked at pembrolizumab (MK-3475) for patients with melanoma. These data were presented by Dr. Antoni Ribas.
- 72% of patients experienced at least disease control.
- As of the last data analysis, 88% of patients who had responded were experiencing a continued response.
- This is characteristic of immunotherapy the effects of the medicine on the immune system should lead to durable control of the disease.
<<<
Recent Videos
Related Content
Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs
January 21st 2025Article
The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Read More
